MapLight Therapeutics (MPLT) Current Deferred Revenue (2024 - 2025)
MapLight Therapeutics (MPLT) posted Current Deferred Revenue of $1.2 million for Q3 2025, down 62.5% sequentially from $3.2 million in Q4 2024.
Powered by 
Analysis
MapLight Therapeutics (MPLT) Current Deferred Revenue (2024 - 2025) Analysis & Trends
MapLight Therapeutics has reported Current Deferred Revenue for 2 years, with the latest figure at $1.2 million in Q3 2025.
- Quarterly Current Deferred Revenue changed N/A year-over-year to $1.2 million in Q3 2025, while the trailing twelve-month figure through Sep 2025 was $1.2 million (changed N/A YoY) and the FY2024 annual result came in at $3.2 million, changed N/A from the prior year.
- Current Deferred Revenue eased to $1.2 million in Q3 2025 per MPLT's latest filing, from $3.2 million in the prior quarter.
- Over five years, Current Deferred Revenue peaked at $3.2 million in Q4 2024 and troughed at $1.2 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | MapLight Therapeutics | 642.40 Mn | 642.40 Mn | - |